能否使EGFRvIII和来自神经元的EGFR成为imipramine的点?
Zesheng Li1, Bo Wang1, Jianjian Wu2
1Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital, Tianjin, China.
Frontiers in pharmacology
|June 16, 2023
概括
三环抗抑郁药,如伊米普拉,显示出治疗质母细胞瘤 (GBM) 的潜力. 这项研究表明,伊米普拉胺可能向EGFRvIII和神经元EGFR,调节瘤微环境和免疫功能.
科学领域:
- 在瘤学瘤学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 三环抗抑郁药 (TCA) 具有有利的安全性,使其适合药物重定位.
- 人们越来越认识到神经参与了癌症的进展,这引起了人们对神经向药物进行癌症治疗的兴趣.
- 在质母细胞瘤 (GBM) 瘤微环境中抗抑郁药作用的精确机制在很大程度上仍未被探索.
研究的目的:
- 研究伊米普拉胺在治疗质母细胞瘤 (GBM) 的分子机制.
- 通过准神经通路,探索TCA作为用于GBM治疗的重定向药物的潜力.
主要方法:
- 采用了多omics方法,包括散装RNA测序和单细胞测序.
- 采用了网络药理学,分子对接和分子动力学模拟.
- 整合了各种计算和实验技术,以阐明药物向相互作用和途径.
主要成果:
- 假设伊米胺治疗向表皮生长因子受体变异III (EGFRvIII) 和神经元EGFR.
- 这项研究表明,伊米普拉胺可能会减少GABAergic突触和囊泡介导释放.
- 这些通路的调节表明,在GBM微环境中,对免疫功能有潜在的影响.
结论:
- 在GBM中,伊米普拉的治疗作用可能涉及向EGFRvIII和神经元EGFR.
- 药物对GABAergic和囊泡过程的作用可能会影响瘤微环境和免疫反应.
- 这些发现为伊米普拉治疗GBM的药理机制提供了新的见解,并提出了新的研究途径.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Enzyme-linked Receptors
78.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.9K
Antiepileptic Drugs: Potassium Channel Activators
218
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
218
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


